卡利尤單抗，Camidanlumab，CAS:921618-45-3， AntibodySystem Laboratories

貨號(hào)：DHB95803

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75440.html

別名：ADCT-301(unconjugated), HuMax-TAC-ADC, CAS: 921618-45-3

簡(jiǎn)介：

Camidanlumab (HuMax-TAC) 是一種 CD25 單克隆抗體。Camidanlumab 靶向細(xì)胞表面抗原 CD25，該抗原在多種血液腫瘤中過(guò)度表達(dá)，在正常組織中表達(dá)有限。 Camidanlumab 可用于合成抗體藥物偶聯(lián)物 (ADCs)，研究包括淋巴瘤和白血病在內(nèi)的多種疾病。

貨號(hào)：DHB95803

產(chǎn)品品牌：Antibodysystem

通用名：Camidanlumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：ADCT-301(unconjugated), HuMax-TAC-ADC

靶點(diǎn);物種：Human CD25/IL2RA

種類：Homo sapiens

受體鑒定：IgG1-kappa

化學(xué)信息：CAS: 921618-45-3

存儲(chǔ)條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma. PMID: 36074313

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. PMID: 34048682

A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. PMID: 33492560

Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. PMID: 32521310

Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. PMID: 32543981

Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine. PMID: 35257078

Current salvage therapies in Hodgkin lymphoma. PMID: 35037568

Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. PMID: 36333463

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. PMID: 36333464

Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond. PMID: 33602008

Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine. PMID: 36800311

The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer-Containing Antibody-Drug Conjugates. PMID: 32669316

CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. PMID: 32912922

Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. PMID: 36702422